Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Panel Shelves Decision on Reimbursement Rate for OTC-Switched Rx
December 1, 2016
- LDP Group Submits Resolution Calling for “Drug Pricing Agency”
December 1, 2016
- HIV Combo Pill Prezcobix OK’ed for NHI Price Listing
December 1, 2016
- Industry, Healthcare Provider Reps Oppose “Annual Revisions” as Payers Hold Off Stance: Chuikyo
December 1, 2016
- Chuikyo at Odds over Price Maintenance Premium
December 1, 2016
- Chuikyo to Discuss “Price-Setting Including NHI Price Increases” Using Cost-Effective Assessments
December 1, 2016
- “Outright” or “Partial”? Annual Revision Debate Rekindled in a Rush to Revamp Drug Pricing
November 30, 2016
- MID-NET Working Group Agrees on Flat Access Fees for Drug Makers’ PMS Use
November 30, 2016
- Shiozaki Hints at Possible Drug Price Survey in Different Method
November 30, 2016
- Before Micatrio, Patient Must Take 3 Contained Compounds for at Least 8 Weeks: MHLW
November 29, 2016
- Japan Ophthalmologists Association Calls for Reductions in NHI Prices of High-Cost Drugs
November 29, 2016
- LDP Study Group Kicks Off to Put Brakes on Hasty Push for Biosimilars
November 28, 2016
- Eltrombopag, Nusinersen Designated as Orphan Drugs
November 28, 2016
- MHLW Advisory Panel OKs Biogen’s Tecfidera, Other Drugs
November 28, 2016
- Annual Price Revision Push Gaining Momentum; PM Wants Pricing Revamp Policy by Year-End
November 28, 2016
- MHLW Panel OKs Celgene’s Apremilast, 2 Other NMEs
November 25, 2016
- MHLW Looks to Extend MID-NET to Cover Clinic Data: Bureau Chief
November 25, 2016
- More Patient Participation Needed to Promote Drug Development, Safety Measures: MHLW Official
November 25, 2016
- Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC
November 25, 2016
- Polaprezinc Ordered to Add Copper Deficiency in ADR List
November 24, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…